Deleted Journal, Год журнала: 2025, Номер unknown, С. 1 - 12
Опубликована: Март 20, 2025
Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), remains a global health challenge despite advances in conventional treatments. The limitations of traditional anti-tuberculosis therapies, such as prolonged treatment duration, drug resistance, and tissue damage, necessitate innovative approaches. Stem cell-based therapies have emerged promising avenue due to their immunomodulatory, regenerative, drug-delivery capabilities. This review discussed the pathogenesis potential various stem cell types, including mesenchymal cells (MSCs), hematopoietic (HSCs), induced pluripotent (iPSCs), management. It delved into mechanisms, immune regulation, repair, targeted delivery. Additionally, this summarized application cell-derived organoid technology establishing vitro models. These organoids, three-dimensional structures derived from cells, mimic architecture function organs like lungs, providing platform study Mtb infection dynamics, host-pathogen interactions, screening. Altogether, therapy, complemented organoid-based models, offers transformative for advancing research, particularly drug-resistant immunocompromised patients.
Язык: Английский